PureTech’s Vedanta raises $27m for microbiome researchUS-based Vedanta Biosciences has raised $27 million in a Series C financing to investigate microbiome-derived therapies for several Share XPureTech’s Vedanta raises $27m for microbiome researchhttps://pharmaphorum.com/news/puretechs-vedanta-raises-27m-for-microbiome-research/
PureTech signs potential $1bn exosome deal with RocheUS biotech PureTech Health has signed a potential billion-dollar deal with Roche based around its exosome technology that Share XPureTech signs potential $1bn exosome deal with Rochehttps://pharmaphorum.com/news/puretech-signs-potential-1bn-exosome-deal-with-roche/
Wellcome Trust awards $8m cash injection to trial schizophrenia drugThe Wellcome Trust has awarded $8 million to PureTech’s Karuna to take its schizophrenia drug into mid-stage trials. Share XWellcome Trust awards $8m cash injection to trial schizophrenia drughttps://pharmaphorum.com/news/wellcome-trust-awards-trial-schizophrenia-drug/
PureTech licenses ‘bacterial cocktail’ to boost cancer immunotherapyPureTech Health is to develop a combination of a microbiome treatment with checkpoint inhibitor immunotherapy to enhance the Share XPureTech licenses ‘bacterial cocktail’ to boost cancer immunotherapyhttps://pharmaphorum.com/news/puretech-develop-bacterial-cancer-immunotherapy/
PureTech’s device could rival Saxenda in obesity marketA new non-invasive device from PureTech Health could help millions of overweight or obese people to slim down, Share XPureTech’s device could rival Saxenda in obesity markethttps://pharmaphorum.com/news/puretech-aims-weight-loss-market-gelesis100/
